Application of IL-18/IL-18BP in diagnosis and treatment of novel coronavirus pneumonia (COVID-19)

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000036661

Enrollment

Unknown

Registered

2020-08-24

Start date

2020-10-30

Completion date

Unknown

Last updated

2020-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 pneumonia

Interventions

Gold Standard:Clinical outcome

Index test:IL-18/IL-18BP

Eligibility

Sex/Gender

All

Age

1 Years to 90 Years

Inclusion criteria

Inclusion criteria: Novel Coronavirus specific IgM and IgG antibodies were positive in serum. Real-time fluorescent RT-PCR detected novel Coronavirus NUCLEic acid positive, or ICU patients and confirmed patients with severe or critical clinical warning indicators indicated by imaging. Eighty patients were confirmed, including 20 patients with severe or critical illness.

Exclusion criteria

Exclusion criteria: 1. Patients with acute cerebral thrombosis and other diseases prone to sudden death; 2. Covid-19novel Coronavirus infection triggers bacterial infection in patients with severe illness; 3. Patients judged by the investigator to be unsuitable for this study.

Design outcomes

Primary

Measure	Time frame
Nucleic acid negative;	—

Countries

China

Contacts

Public ContactMingquan Guo

Shanghai Public Health Clinical Center

guomingquan@shphc.org.cn+86 18017137245

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026